Barclays
DYN icon

Barclays’s Dyne Therapeutics DYN Stock Holding History

Barclays’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$826K Buy
37,180
+611
+2% +$11.4K ﹤0.01% 2909
2026
Q1 		$663K Sell
36,569
-412,089
-92% -$7.11M ﹤0.01% 3011
2025
Q4 		$8.78M Sell
448,658
-32,043
-7% -$607K ﹤0.01% 1776
2025
Q3 		$6.08M Buy
480,701
+160,211
+50% +$1.83M ﹤0.01% 2047
2025
Q2 		$3.05M Buy
320,490
+89,266
+39% +$983K ﹤0.01% 2528
2025
Q1 		$2.42M Buy
231,224
+38,985
+20% +$558K ﹤0.01% 2486
2024
Q4 		$4.53M Sell
192,239
-15,070
-7% -$446K ﹤0.01% 2249
2024
Q3 		$7.45M Buy
207,309
+128,246
+162% +$5.1M ﹤0.01% 1708
2024
Q2 		$2.79M Sell
79,063
-4,909
-6% -$143K ﹤0.01% 1904
2024
Q1 		$2.38M Sell
83,972
-69,379
-45% -$1.57M ﹤0.01% 2426
2023
Q4 		$2.04M Buy
153,351
+53,777
+54% +$525K ﹤0.01% 2908
2023
Q3 		$892K Buy
99,574
+17,603
+21% +$190K ﹤0.01% 2412
2023
Q2 		$922K Buy
81,971
+49,883
+155% +$588K ﹤0.01% 2364
2023
Q1 		$370K Buy
32,088
+7,845
+32% +$102K ﹤0.01% 3470
2022
Q4 		$281K Buy
24,243
+7,164
+42% +$82.9K ﹤0.01% 3666
2022
Q3 		$217K Sell
17,079
-62,420
-79% -$716K ﹤0.01% 3149
2022
Q2 		$547K Buy
79,499
+60,313
+314% +$415K ﹤0.01% 2793
2022
Q1 		$185K Buy
+19,186
New +$163K ﹤0.01% 3467

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Barclays's DYN Position: Q2 2026 in Review

Barclays increased its Dyne Therapeutics (DYN) stake by 1.7% in Q2 2026, buying an estimated $11.4K and bringing the position to 37,180 shares worth $826K. The position accounts for ﹤0.01% of the portfolio, ranked #2909.

Barclays first reported a position in DYN in Q1 2022 and has held it in 18 quarters since. The position peaked at $8.78M in Q4 2025. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Barclays held 37,180 shares of Dyne Therapeutics worth $826K as of Q2 2026.
  • Barclays bought 611 Dyne Therapeutics shares in Q2 2026, an estimated $11.4K.
  • Dyne Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2909 holding.
  • Barclays first reported a position in Dyne Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Dyne Therapeutics position peaked at $8.78M in Q4 2025.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.